Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M91,621Revenue (TTM) $M30,390Net Margin (%)44.4Altman Z-Score3.7
Enterprise Value $M59,241EPS (TTM) $9.9Operating Margin %58.0Piotroski F-Score5
P/E(ttm)7.0Beneish M-Score-2.6Pre-tax Margin (%)56.3Higher ROA y-yN
Price/Book4.710-y EBITDA Growth Rate %--Quick Ratio4.0Cash flow > EarningsN
Price/Sales3.15-y EBITDA Growth Rate %51.7Current Ratio4.2Lower Leverage y-yY
Price/Free Cash Flow7.6y-y EBITDA Growth Rate %-13.7ROA % (ttm)25.7Higher Current Ratio y-yY
Dividend Yield %2.6PEG0.1ROE % (ttm)80.7Less Shares Outstanding y-yY
Payout Ratio %17.0Shares Outstanding M1,310ROIC % (ttm)67.0Gross Margin Increase y-yN

Gurus Latest Trades with GILD

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

GILD is held by these investors:



GILD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MARTIN JOHN CExecutive Chairman 2017-02-01Sell73,333$72.57-3.62view
MARTIN JOHN CExecutive Chairman 2017-01-03Sell73,337$73.59-4.96view
MARTIN JOHN CExecutive Chairman 2016-12-01Sell100,000$73.33-4.62view
MADIGAN JOHN WDirector 2016-11-18Sell105,000$74.86-6.57view
Alton Gregg HEVP Comm&Acs ALA, Corp&Med Aff 2016-11-09Sell10,000$79-11.47view
MARTIN JOHN CExecutive Chairman 2016-11-01Sell100,000$73.76-5.18view
MARTIN JOHN CExecutive Chairman 2016-10-03Sell100,000$77.63-9.91view
Alton Gregg HEVP Comm&Acs ALA, Corp&Med Aff 2016-09-22Sell5,000$81.84-14.54view
MILLIGAN JOHN FPresident and CEO 2016-09-06Sell70,000$77.74-10.03view
MARTIN JOHN CExecutive Chairman 2016-09-01Sell100,000$77.48-9.73view

Quarterly/Annual Reports about GILD:

News about GILD:

Articles On GuruFocus.com
Gilead Sciences Raises Dividend by Double Digits Feb 22 2017 
10 Undervalued Stocks for the Enterprising Investor Feb 16 2017 
Under the Microscope: Gilead's Recent Dividend Increase Feb 15 2017 
Consider Gilead Sciences Feb 14 2017 
Gilead Sciences, Fossil Reach 3-Year Low Prices Feb 12 2017 
How BioVie, Conatus and PhaseRX Tackle Liver Diseases Feb 08 2017 
10 Low PE Stock Picks for the Enterprising Investor Feb 04 2017 
5 Companies Near 52-Week Lows Feb 03 2017 
John Paulson's Bargain Stock Jan 30 2017 
10 Undervalued Stocks for the Enterprising Investor Jan 26 2017 

More From Other Websites
Gilead, AbbVie Could Perk Up On Merck's Hep C Downfall: Leerink Feb 24 2017
NASH Is Todd Hagopian's Top Biotech Sub-Sector For 2017 Feb 24 2017
Ten Stocks That Still Look Cheap Feb 24 2017
7 Ultra-Cheap Value Stocks to Buy Now Feb 24 2017
Gilead Sciences Expects a Fall in Its HCV Product Sales in 2017 Feb 24 2017
AbbVie Stronger Bet Than Gilead, Amgen — At Least Until 2020: Leerink Feb 23 2017
Gilead Sciences, Inc. (GILD) EPCLUSA Access To Be Provided In Ontario For Treatment Of Hepatitis C Feb 23 2017
Baby Boomers: Gilead’s New Hep C Target Group Feb 23 2017
This Strategy Could Boost GILD’s HIV Franchise Revenue in 2017 Feb 23 2017
These Regimens Are Expected to See Solid Global Demand in 2017 Feb 23 2017
Big Pharma Quietly Enlists Leading Professors to Justify $1,000-a-Day Drugs Feb 23 2017
Solid Uptake of This Drug Could Drive Gilead’s 2017 Product Sales Feb 23 2017
Cramer: Why Gilead could be a value trap Feb 22 2017
Gilead Sciences Raises Dividend by Double Digits Feb 22 2017
Gilead, Glaxo Pitted In HIV Battle; Both Struggle Vs. Standard Drugs Feb 22 2017
Gilead Sciences Expects to Witness an Earnings Fall in 2017 Feb 22 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)